RIL
CMPX icon

Rothschild Investment LLC’s Compass Therapeutics CMPX Stock Holding History

Rothschild Investment LLC’s Portfolio CMPX Stock Details CMPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.48K Buy
279
+115
+70% +$664 ﹤0.01% 2696
2025
Q4 		$881 Buy
164
+44
+37% +$203 ﹤0.01% 2722
2025
Q3 		$420 Hold
120
– – ﹤0.01% 2870
2025
Q2 		$312 Buy
+120
New +$247 ﹤0.01% 2852

Other funds holding CMPX

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Rothschild Investment LLC's CMPX Position: Q1 2026 in Review

Rothschild Investment LLC increased its Compass Therapeutics (CMPX) stake by 70% in Q1 2026, buying an estimated $664 and bringing the position to 279 shares worth $1.48K. The position accounts for ﹤0.01% of the portfolio, ranked #2696.

Rothschild Investment LLC first reported a position in CMPX in Q2 2025 and has held it in 4 quarters since. 201 funds tracked by Wall St. Rank hold CMPX as of Q1 2026.

  • Rothschild Investment LLC held 279 shares of Compass Therapeutics worth $1.48K as of Q1 2026.
  • Rothschild Investment LLC bought 115 Compass Therapeutics shares in Q1 2026, an estimated $664.
  • Compass Therapeutics made up ﹤0.01% of Rothschild Investment LLC's portfolio in Q1 2026, its #2696 holding.
  • Rothschild Investment LLC first reported a position in Compass Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • 201 funds tracked by Wall St. Rank held Compass Therapeutics as of Q1 2026.

Based on Rothschild Investment LLC's 13F filing for Q1 2026, filed 7 May 2026.